A Post-Authorization, Long-term Study of Ozanimod Real-world Safety
A Post-Authorization, Long-term Study of Ozanimod Real-world Safety
Active, not recruiting · NCT05605782 · Registry updated 2025-06-26Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Post-Authorization, Long-term Study of Ozanimod Real-world Safety | CNS demyelinating autoimmune disease, autoimmune disease, autoimmune disorder of the nervous system, demyelinating disease, eye disorder, immune system disorder, macular degeneration, macular retinal edema, multiple sclerosis, neoplasm, nervous system disorder, relapsing-remitting multiple sclerosis, retinal degeneration, retinal disorder | Active, not recruiting | Not stated | 2025-06-26 | NCT05605782 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Bristol-Myers Squibb | 422 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Evidera | Bethesda | United States | 2 |